CONMED (CNMD) Receiving Positive Press Coverage, Report Shows

Media headlines about CONMED (NASDAQ:CNMD) have trended positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. CONMED earned a daily sentiment score of 0.25 on Accern’s scale. Accern also assigned media headlines about the medical technology company an impact score of 46.625379850205 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:

A number of equities research analysts recently commented on CNMD shares. Zacks Investment Research lowered shares of CONMED from a “hold” rating to a “sell” rating in a report on Monday, November 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $58.00 target price on shares of CONMED in a research report on Friday, November 17th. BidaskClub downgraded shares of CONMED from a “sell” rating to a “strong sell” rating in a research report on Wednesday, December 27th. KeyCorp reaffirmed a “hold” rating on shares of CONMED in a research report on Friday, November 3rd. Finally, Piper Jaffray Companies reaffirmed a “hold” rating and issued a $46.00 target price on shares of CONMED in a research report on Friday, November 3rd. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $59.00.

CONMED (NASDAQ CNMD) opened at $61.27 on Monday. The firm has a market cap of $1,711.51, a price-to-earnings ratio of 31.10, a P/E/G ratio of 2.49 and a beta of 0.74. CONMED has a 12-month low of $39.74 and a 12-month high of $64.99. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.56 and a quick ratio of 1.49.

CONMED (NASDAQ:CNMD) last released its earnings results on Wednesday, January 31st. The medical technology company reported $0.69 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.04. The business had revenue of $222.60 million during the quarter, compared to the consensus estimate of $212.17 million. CONMED had a net margin of 6.97% and a return on equity of 9.15%. The firm’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter last year, the firm earned $0.54 earnings per share. equities analysts forecast that CONMED will post 2.14 EPS for the current year.

In other news, CFO Luke A. Pomilio sold 1,962 shares of CONMED stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $60.25, for a total value of $118,210.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jo Ann Golden sold 3,000 shares of CONMED stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $63.90, for a total transaction of $191,700.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 22,985 shares of company stock valued at $1,452,208. 2.62% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/19/conmed-cnmd-receiving-positive-press-coverage-report-shows.html.

CONMED Company Profile

CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.

Insider Buying and Selling by Quarter for CONMED (NASDAQ:CNMD)

Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply